2022-09-02 BioEcho Life Sciences announces expansion with new US subsidiary
The BioEcho subsidiary in the biotechnology hub of Boston is a decisive step in the company’s plan to serve a worldwide growing customer base with best-in-class products and services. The company is a specialized solution provider for the extraction and analysis of nucleic acids. BioEcho Life Sciences Inc. will be operational from 1st of September 2022.
BioEcho Is Now a Member of VDGH
Effective January 1, 2022, BioEcho joined the German Diagnostics Industry Association (VDGH). VDGH has more than 100 corporate members that manufacture or sell diagnostics and life science research products.
New Company Video Out Now!
Learn more about the success story and mission of BioEcho and meet the team.
Mobile Laboratory for COVID-19 PCR Testing
BioEcho launches a mobile test station for fastest SARS-CoV-2 PCR analysis – independent of the location.
BioEcho launches EchoLUTION™ FFPE DNA Kit for a simplified DNA extraction from FFPE samples
DNA extraction from formalin-fixed paraffin-embedded (FFPE) tissues is an essential step when performing downstream applications used in drug development, biomarker investigation, pathology, as well as in clinical diagnostics and cancer research.
BioEcho Achieves My Green Lab® Certification
The BioEcho Life Sciences R&D department has successfully completed the My Green Lab Certification Program as a Green Level Certified Lab, which is the highest certification level.